Altimmune Inc (ALT)
8.455
-1.06
(-11.09%)
USD |
NASDAQ |
Nov 14, 16:00
8.43
-0.02
(-0.30%)
After-Hours: 17:33
Altimmune Research and Development Expense (Quarterly): 21.16M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 21.16M |
| March 31, 2024 | 21.49M |
| December 31, 2023 | 16.91M |
| September 30, 2023 | 18.39M |
| June 30, 2023 | 13.25M |
| March 31, 2023 | 17.25M |
| December 31, 2022 | 19.18M |
| September 30, 2022 | 20.26M |
| June 30, 2022 | 15.99M |
| March 31, 2022 | 15.10M |
| December 31, 2021 | 20.18M |
| September 30, 2021 | 29.21M |
| June 30, 2021 | 13.27M |
| March 31, 2021 | 11.88M |
| December 31, 2020 | 8.951M |
| September 30, 2020 | 17.04M |
| June 30, 2020 | 16.59M |
| March 31, 2020 | 7.188M |
| December 31, 2019 | 2.873M |
| September 30, 2019 | 8.730M |
| June 30, 2019 | 2.945M |
| March 31, 2019 | 3.218M |
| December 31, 2018 | 3.065M |
| September 30, 2018 | 4.729M |
| June 30, 2018 | 4.919M |
| Date | Value |
|---|---|
| March 31, 2018 | 5.747M |
| December 31, 2017 | 4.460M |
| September 30, 2017 | 5.906M |
| June 30, 2017 | 5.255M |
| March 31, 2017 | 2.786M |
| December 31, 2016 | 2.376M |
| September 30, 2016 | 2.401M |
| June 30, 2016 | 1.382M |
| March 31, 2016 | 1.029M |
| December 31, 2015 | 1.172M |
| September 30, 2015 | 1.126M |
| June 30, 2015 | 1.222M |
| March 31, 2015 | 1.614M |
| December 31, 2014 | 1.791M |
| September 30, 2014 | 1.729M |
| June 30, 2014 | 2.373M |
| March 31, 2014 | 3.427M |
| December 31, 2013 | 4.098M |
| September 30, 2013 | 2.556M |
| June 30, 2013 | 3.402M |
| March 31, 2013 | 5.234M |
| December 31, 2012 | 4.747M |
| September 30, 2012 | 5.139M |
| June 30, 2012 | 4.919M |
| March 31, 2012 | 4.705M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.873M
Minimum
Dec 2019
29.21M
Maximum
Sep 2021
16.11M
Average
16.91M
Median
Dec 2023
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly and Co | 2.734B |
| Viking Therapeutics Inc | 22.78M |
| Amgen Inc | 1.45B |
| Avid Bioservices Inc | -- |
| NovaBay Pharmaceuticals Inc | 0.009M |